The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body.

Investor reaction to the deal was muted, with BMO Capital Markets analysts saying they "continue to look for more" from ...

BMS, which already has two FDA-approved CAR T-cell therapies, is eyeing entry into the growing in vivo market.

Bristol Myers Squibb has agreed to acquire Orbital Therapeutics, a privately held biotechnology company pioneering a new ...

Bristol Myers Squibb (BMY) has agreed to acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion ...

As the world reached out to congratulate San Francisco-based researcher Dr. Fred Ramsdell on being awarded the Nobel Prize in Medicine, he was radio silent, as he was off-grid camping in Yellowstone ...

Bristol Myers Squibb (BMS) announced a definitive agreement in which BMS will acquire Orbital Therapeutics along with its ...

Bristol Myers Squibb will acquire Orbital Therapeutics for $1.5B, expanding its RNA medicine and in vivo CAR T-cell therapy capabilities.

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies ...

Bristol Myers Squibb (BMY) stock was down on Friday after the biopharmaceutical company announced its acquisition of private ...

This age-old drink, made with simple cumin and coriander seeds, works like a pre-festive reset for your body - helping your ...

(Reuters) -Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital ...